Adipotide
Prohibitin-targeting peptide 1 (Prohibitin-TP01)
Adipotide is a revolutionary experimental vascular-targeting peptidomimetic designed to induce selective apoptosis in blood vessels supplying white adipose tissue. Also known as Prohibitin-TP01, FTPP (Fat-Targeted Proapoptotic Peptide), or TP-1, it represents a completely novel approach to weight management through direct fat cell elimination rather than appetite suppression. While clinical development was discontinued in 2019 due to nephrotoxicity concerns, preclinical studies demonstrated remarkable efficacy with up to 30% weight reduction in rodent models and 11% weight loss in primate studies over just 28 days.
Clinical Benefits
Mechanism of Action
Adipotide employs a unique dual-domain architecture for targeted adipose tissue elimination. The N-terminal CKGGRAKDC targeting domain functions as a vascular homing peptide that binds specifically to prohibitin-1 and annexin A2 (ANXA2) receptors highly expressed on endothelial cells of blood vessels supplying white adipose tissue. Following receptor-mediated binding and cellular internalization, the C-terminal D(KLAKLAK)₂ proapoptotic domain disrupts mitochondrial membranes through cationic amphipathic peptide interactions, triggering cytochrome c release and caspase-dependent apoptosis. This leads to endothelial cell death, vascular regression, and subsequent secondary apoptosis of downstream adipocytes due to ischemia and nutrient deprivation. The process is highly selective for white adipose tissue vasculature due to the specific expression pattern of prohibitin-1 receptors.
Proven Results
Medical Disclaimer
CRITICAL WARNING: Adipotide clinical development was permanently discontinued due to unacceptable nephrotoxicity. All human trials were terminated early. This information is for educational purposes only. Adipotide is NOT approved for any human use and carries severe kidney damage risks. Consult healthcare providers for approved weight management alternatives.